DENVER–()–MedPharm Holdings, a number one hashish researcher and producer, declares that they’ve been granted a patent at this time for a novel invention: a water-soluble powdered cannabinoid and/or terpene extract.

The inventor of MedPharm’s powdered cannabinoid formulation, Scott Karolchyk, MS, RPh, has been growing varied well being and pharmaceutical formulations for over 18 years, and has been granted over a dozen patents.

The U.S. patent quantity 10,980,743 is without doubt one of the firm’s many innovations and entails a course of that leverages MedPharm’s Lipophilic Enhanced Absorption Formula (L.E.A.F) expertise to create the water-soluble powdered cannabinoid extract. The infused powder stays steady for no less than one yr and will be compounded into varied pharmaceutical grade and/or over-the-counter formulations (i.e., drinks, candies, emulsions) with various bulk powder densities.

“What an amazing discovery, and a perfect fit for us,” Albert Gutierrez, CEO of MedPharm, says. “From the beginning, about four years ago now, we have always worked to find more effective, bioavailable, and safer cannabis dosage forms for various medical uses. This invention checks all the boxes of what we want: a good, safe, effective, and versatile cannabis product that is absorbed more quickly than current products on the market. All of this is accomplished through an original process that is cheaper and easier to implement than other methods of solubilizing cannabinoids.”

Additionally, the invention of this powdered cannabinoid course of permits extracted cannabinoid oil for use in formulations containing dry powders akin to tablets, capsules, injectables, dry powder inhalers, edibles, drinks, and powdered mixes. The powder’s bulk density will be simply modified to accommodate the event of the ultimate dosage kind. “The process can be applied to a range of core materials in numerous particle sizes, shapes, and densities. No matter the shape, whether crystalline, spherical, irregular, amorphous, or other, the process can create unique formulations to achieve the desired properties. Understanding the flow related properties, particle size, and density is critical in the processing of these powders for their intended formulations. This invention eliminates most trial and error,” Gutierrez says.

With this invention, Gutierrez says, MedPharm has once more efficiently tapped into the leading edge work of its hashish researchers and chemists to search out out extra in regards to the “What, Why and How?” of hashish compounds and their medicinal results on the human physique. “Helping people live better, happier, and more productive lives has always been the focus of MedPharm.”

The invention comes at a time when MedPharm has been steadily gaining recognition for its present line of hashish merchandise. In November, 2020, the corporate gained awards for “Top Selling Cartridge” in Colorado for their BATCH cartridge and, for the second yr in a row, “Top Selling Tincture” in Colorado for their Aliviar 20:1 tincture.

Both awards have been a part of an annual hashish award collection by LeafLink, a nationwide wholesale platform used within the hashish trade that connects over 1,700 hashish manufacturers with over 5,600 licensed retailers in 26 territories throughout North America.

About MedPharm:

MedPharm has a 15,000-square-foot manufacturing, analysis and improvement laboratory and hashish processing facility in Denver, Colorado. Since starting operations in 2017, MedPharm has grown to a employees of 44 individuals. The firm gives hashish pharmaceutical-type merchandise in an authorized present Good Manufacturing Practices (cGMP) and Good Agricultural Practices (GAP) facility that features cultivation, pre-formulation, formulation improvement, small scale industrial manufacturing, analytical technique improvement and validation, routine high quality management evaluation and stability research. MedPharm creates pharmaceutical-grade dosage kinds and produces substances using pharmaceutical expertise for use within the supply of hashish compounds. MedPharm focuses on neuropharmacology with a deal with Alzheimer’s illness and dementia. MedPharm obtained the primary hashish analysis license issued to the state of Colorado in October, 2018. MedPharm Research, a completely owned subsidiary, additionally has pending federal functions for Bulk Manufacturing and Schedule I Research licenses to offer and use hashish and hashish dosage kinds for analysis functions. More info will be discovered about MedPharm at: www.medpharmholdings.com.

Source link